Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
THE BEST BLACK FRIDAY DEAL YET (Ad)
Best Buy Proves Brick and Mortar is Here to Stay
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
THE BEST BLACK FRIDAY DEAL YET (Ad)
Best Buy Proves Brick and Mortar is Here to Stay
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
THE BEST BLACK FRIDAY DEAL YET (Ad)
Best Buy Proves Brick and Mortar is Here to Stay
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Bird flu prompts slaughter of 1.8M chickens in Nebraska
THE BEST BLACK FRIDAY DEAL YET (Ad)
Best Buy Proves Brick and Mortar is Here to Stay
US-England World Cup game seen by 19.98M on US television
NASDAQ:EXAI

Exscientia - EXAI Stock Forecast, Price & News

$5.73
+0.33 (+6.11%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$5.35
$5.78
50-Day Range
$5.40
$8.94
52-Week Range
$5.35
$24.99
Volume
81,400 shs
Average Volume
171,060 shs
Market Capitalization
$701.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67

Exscientia MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
173.4% Upside
$15.67 Price Target
Short Interest
Bearish
1.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.77) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

987th out of 1,044 stocks

Biological Products, Except Diagnostic Industry

170th out of 174 stocks

EXAI stock logo

About Exscientia (NASDAQ:EXAI) Stock

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Receive EXAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter.

EXAI Stock News Headlines

Barclays Lowers Exscientia (NASDAQ:EXAI) Price Target to $12.00
THE BEST BLACK FRIDAY DEAL YET
This Black Friday, you can save 95% off of a 1-year membership to Brad Thomas’s Intelligent Income Investor. This service is geared toward helping you collect the safest dividend income in the market. It all starts with Brad’s “SWAN” portfolio, of the 10 best companies to own through any market.
THE BEST BLACK FRIDAY DEAL YET
This Black Friday, you can save 95% off of a 1-year membership to Brad Thomas’s Intelligent Income Investor. This service is geared toward helping you collect the safest dividend income in the market. It all starts with Brad’s “SWAN” portfolio, of the 10 best companies to own through any market.
See More Headlines
Receive EXAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter.

EXAI Company Calendar

Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/22/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EXAI
Fax
N/A
Employees
285
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.67
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+173.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-67,700,000.00
Net Margins
-405.81%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$37 million
Book Value
$6.61 per share

Miscellaneous

Free Float
N/A
Market Cap
$701.70 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Prof. Andrew L. Hopkins DPHIL (Age 49)
    FRSE FRSC, Founder, CEO & Exec. Director
  • Mr. Ben Ashwell-Fryer
    VP of Fin.
  • Mr. Ben R. Taylor (Age 45)
    CFO, Chief Strategy Officer & Exec. Director
  • Ms. Heather Togwell
    Operations Mang.
  • Dr. David Hallett Ph.D. (Age 51)
    Chief Operating Officer
  • Dr. Garry Pairaudeau Ph.D. (Age 55)
    Chief Technology Officer
  • Ms. Eileen Jennings-Brown
    Chief Information Officer
  • Ms. Sara Sherman
    VP of Investor Relations
  • Mr. Dan Ireland
    VP of Legal
  • Mr. Chris Thomas
    VP of People













EXAI Stock - Frequently Asked Questions

Should I buy or sell Exscientia stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EXAI shares.
View EXAI analyst ratings
or view top-rated stocks.

What is Exscientia's stock price forecast for 2023?

3 brokerages have issued 1-year target prices for Exscientia's stock. Their EXAI share price forecasts range from $12.00 to $20.00. On average, they predict the company's share price to reach $15.67 in the next year. This suggests a possible upside of 173.4% from the stock's current price.
View analysts price targets for EXAI
or view top-rated stocks among Wall Street analysts.

How have EXAI shares performed in 2022?

Exscientia's stock was trading at $19.76 at the beginning of 2022. Since then, EXAI shares have decreased by 71.0% and is now trading at $5.73.
View the best growth stocks for 2022 here
.

When is Exscientia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our EXAI earnings forecast
.

When did Exscientia IPO?

(EXAI) raised $291 million in an initial public offering on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share.

What is Exscientia's stock symbol?

Exscientia trades on the NASDAQ under the ticker symbol "EXAI."

Who are Exscientia's major shareholders?

Exscientia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (3.98%), Platinum Investment Management Ltd. (2.30%), Marshall Wace LLP (1.34%), Pictet Asset Management SA (1.17%), Price T Rowe Associates Inc. MD (0.71%) and Nan Fung Group Holdings Ltd (0.70%).

How do I buy shares of Exscientia?

Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exscientia's stock price today?

One share of EXAI stock can currently be purchased for approximately $5.73.

How much money does Exscientia make?

Exscientia (NASDAQ:EXAI) has a market capitalization of $701.70 million and generates $37 million in revenue each year. The company earns $-67,700,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does Exscientia have?

The company employs 285 workers across the globe.

How can I contact Exscientia?

The official website for the company is www.exscientia.ai. The company can be reached via phone at 44-0-18-6581-8941 or via email at investors@exscientia.ai.

This page (NASDAQ:EXAI) was last updated on 11/28/2022 by MarketBeat.com Staff